Showing results (81-90 of 197) with videos related to

Sort By:
Pageof 20
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
The Evolving Landscape of Psoriasis TreatmentApril W Armstrong, Kenneth B Gordon, M Alan Menter, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Common and Not-So-Common Comorbidities of PsoriasisM Alan Menter, April W Armstrong, Kenneth B Gordon, et al.
Archives of Dermatology|December 17, 2003
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell countsKenneth B Gordon, Akshay K Vaishnaw, John O'Gorman, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.
The Journal of Dermatological Treatment|March 8, 2017
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumabBoni E Elewski, Lluís Puig, Margaret Mordin, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2026
Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World EvidenceMark G Lebwohl, James G Krueger, John Y Koo, et al.
Drug Safety|February 11, 2019
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsSubrata Ghosh, Lianne S Gensler, Zijiang Yang, et al.
Journal of the American Academy of Dermatology|June 20, 2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitisDonald Belsito, David C Wilson, Erin Warshaw, et al.
The Journal of Dermatological Treatment|February 7, 2020
Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis RegistryAbby S Van Voorhees, Marc A Mason, Leslie R Harrold, et al.
Drug Safety|April 24, 2019
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsSubrata Ghosh, Lianne S Gensler, Zijiang Yang, et al.
Pageof 20